Business Context and Reporting Period
Company: Techne Corporation (BIO-TECHNE Corp)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 1997
Operations: The Company operates through two primary subsidiaries: Research and Diagnostic Systems, Inc. (R&D Systems) in Minneapolis, MN, and R&D Systems Europe Ltd. in Abingdon, England. R&D Systems comprises Biotechnology (cytokines, antibodies, assay kits) and Hematology (controls and calibrators) divisions. The Company declared a two-for-one stock split effective November 17, 1997; all share data in this report is restated to reflect this split.
Key Financial Metrics
| Metric | Q1 FY1998 (Ended 9/30/97) | Q1 FY1997 (Ended 9/30/96) |
|---|---|---|
| Net Sales | $15,537,143 | $14,026,978 |
| Gross Margin | $10,991,237 (70.7%) | $9,248,848 (65.9%) |
| Net Earnings | $3,262,382 | $2,175,269 |
| Earnings Per Share (Diluted) | $0.17 | $0.11 |
| Cash from Operating Activities | $5,303,124 | $2,592,426 |
| Cash & Short-Term Investments | $28,733,964 | $24,752,257 (as of 6/30/97) |
| Total Debt | $0 | $0 |
Liquidity: The Company maintains an unsecured line of credit of $750,000 with no borrowings outstanding. Cash and short-term investments increased by approximately $4 million during the quarter.
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 11% ($1.51 million) year-over-year. R&D Systems sales rose 18%, driven by cytokines, antibodies, and new hematology OEM customers. R&D Europe sales declined 7% due to the discontinuance of a molecular biology product line, though continuing product lines grew 17%.
- Margin Expansion: Gross margin percentage improved from 65.9% to 70.7%. This was attributed to a shift toward higher-margin products and the cessation of royalty payments to Amgen Inc. in August 1996.
- Expense Management: Selling, general, and administrative (SG&A) expenses increased 21% due to occupancy and personnel costs at R&D Systems and increased marketing. Conversely, Research and Development (R&D) expenses decreased 14% ($417,000), primarily due to reduced payments under a joint research agreement in Europe and a transfer of R&D activities to the U.S. facility.
- Profitability: Earnings before income taxes increased 51% ($1.6 million) to $4.72 million, resulting in a 50% increase in net earnings.
Outlook, Risks, and Management Commentary
- Capital Allocation: The Company is accumulating cash for future expansion. Planned capital additions for the remainder of fiscal 1998 are approximately $2 million, to be funded by existing cash and operating flows. This includes leasehold improvements for facility expansion.
- Stock Repurchase: The Company has extended its stock repurchase program, planning to purchase and retire up to an additional $5,000,000 of common stock. Through November 1, 1997, $4.81 million had been repurchased under the original program.
- Dividends: The Company has never paid cash dividends and has no plans to do so in fiscal 1998.
- Risks: Key risks include the acceptance of new biotechnology and hematology products, price competition from growing numbers of cytokine producers, and the retention of hematology OEM and proficiency survey business. Management also notes the impact of research directions by customers.
- Accounting Changes: The Company will adopt SFAS No. 128 (Earnings Per Share) effective December 31, 1997, and SFAS No. 131 (Segment Reporting) effective July 1, 1998.
Investor Verification Checklist
- Verify the impact of the two-for-one stock split on share counts and EPS calculations in future filings.
- Monitor the success of new OEM customers in the Hematology division to confirm revenue sustainability.
- Track the execution of the $5 million stock repurchase program and its effect on share count.
- Assess the performance of R&D Europe's continuing product lines following the discontinuance of the molecular biology line.
- Review upcoming adoption of SFAS No. 128 and SFAS No. 131 for changes in financial presentation.